Research Analysts’ Recent Ratings Updates for Insmed (INSM)

Insmed (NASDAQ: INSM) has recently received a number of price target changes and ratings updates:

• 3/6/2025 – Insmed had its price target raised by analysts at UBS Group AG from $105.00 to $110.00. They now have a “buy” rating on the stock.
• 2/25/2025 – Insmed is now covered by analysts at Royal Bank of Canada. They set an “outperform” rating and a $100.00 price target on the stock.
• 2/25/2025 – Insmed had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $101.00 price target on the stock.
• 2/21/2025 – Insmed had its price target raised by analysts at Truist Financial Co. from $105.00 to $108.00. They now have a “buy” rating on the stock.
• 2/21/2025 – Insmed had its price target lowered by analysts at Stifel Nicolaus from $97.00 to $96.00. They now have a “buy” rating on the stock.
• 2/21/2025 – Insmed had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
• 2/19/2025 – Insmed had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 2/19/2025 – Insmed had its price target raised by analysts at Wells Fargo & Company from $85.00 to $107.00. They now have an “overweight” rating on the stock.
• 2/11/2025 – Insmed had its price target raised by analysts at Stifel Nicolaus from $88.00 to $97.00. They now have a “buy” rating on the stock.
• 2/7/2025 – Insmed had its price target raised by analysts at JPMorgan Chase & Co. from $83.00 to $92.00. They now have an “overweight” rating on the stock.
• 2/7/2025 – Insmed had its price target raised by analysts at Guggenheim from $95.00 to $101.00. They now have a “buy” rating on the stock.
• 2/6/2025 – Insmed had its price target raised by analysts at Morgan Stanley from $85.00 to $90.00. They now have an “overweight” rating on the stock.

Insmed Stock Performance

Insmed stock opened at $73.70 on Wednesday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a 50 day moving average of $75.83 and a 200-day moving average of $73.71. The stock has a market cap of $13.34 billion, a P/E ratio of -13.18 and a beta of 1.28. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. On average, analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insider Activity

In related news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the transaction, the insider now owns 97,083 shares in the company, valued at $7,766,640. This trade represents a 48.42 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the sale, the chief executive officer now owns 384,960 shares in the company, valued at $26,885,606.40. This represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 550,957 shares of company stock valued at $42,859,028. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Assetmark Inc. grew its stake in Insmed by 12.9% in the third quarter. Assetmark Inc. now owns 26,053 shares of the biopharmaceutical company’s stock valued at $1,902,000 after purchasing an additional 2,975 shares in the last quarter. Atria Investments Inc raised its holdings in Insmed by 61.7% in the 3rd quarter. Atria Investments Inc now owns 4,985 shares of the biopharmaceutical company’s stock valued at $364,000 after acquiring an additional 1,902 shares in the last quarter. State of New Jersey Common Pension Fund D boosted its stake in Insmed by 5.2% during the third quarter. State of New Jersey Common Pension Fund D now owns 59,623 shares of the biopharmaceutical company’s stock worth $4,352,000 after buying an additional 2,962 shares in the last quarter. Los Angeles Capital Management LLC increased its stake in Insmed by 164.8% in the third quarter. Los Angeles Capital Management LLC now owns 10,179 shares of the biopharmaceutical company’s stock valued at $743,000 after acquiring an additional 6,335 shares during the period. Finally, WCM Investment Management LLC lifted its stake in Insmed by 58.6% during the third quarter. WCM Investment Management LLC now owns 148,330 shares of the biopharmaceutical company’s stock worth $10,751,000 after purchasing an additional 54,806 shares during the period.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.